Mauna Kea Technologies Revenue and Competitors

Allston,

Location

$60.5M

Total Funding

Estimated Revenue & Valuation

  • Mauna Kea Technologies's estimated annual revenue is currently $45.5M per year.(i)
  • Mauna Kea Technologies's estimated revenue per employee is $313,750
  • Mauna Kea Technologies's total funding is $60.5M.

Employee Data

  • Mauna Kea Technologies has 145 Employees.(i)
  • Mauna Kea Technologies grew their employee count by -1% last year.

Mauna Kea Technologies's People

NameTitleEmail/Phone
1
Chief Scientific OfficerReveal Email/Phone
2
VP, Global Marketing & U.S. SalesReveal Email/Phone
3
Human Resources DirectorReveal Email/Phone
4
Quality DirectorReveal Email/Phone
5
Chief Innovation OfficerReveal Email/Phone
6
Director Sales, USReveal Email/Phone
7
Chief Technology OfficerReveal Email/Phone
8
Chief Operating OfficerReveal Email/Phone
9
Sr. Clinical Account ManagerReveal Email/Phone
10
Global Marketing ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is Mauna Kea Technologies?

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Companyᅢᄁ¬ツᆲ¬トᄁs flagship product, Cellvizio, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, and China.

keywords:N/A

$60.5M

Total Funding

145

Number of Employees

$45.5M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mauna Kea Technologies News

2022-04-20 - Minimally Invasive Biopsy Technologies Market Size And Analysis ...

Top Companies Covered In This Report: Chronix Biomedical, Biocept, Inc., F. Hoffmann-La Roche Ltd, Mauna Kea Technologies, Veracyte, Inc.,...

2022-04-19 - Mauna Kea Technologies Publishes Q1 2022 Sales and Its 2021 ...

Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY), inventor of Cellvizio®, the multidisciplinary probe and needle confocal...

2022-04-13 - Mauna Kea Technologies Announces First of Its Kind U.S. FDA 510 ...

Mauna Kea Technologies (Euronext: MKEA, 'Mauna Kea') inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser...

2021-10-04 - Mauna Kea Technologies : Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the ERS International Congress 2021

Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021 Further validation of how Cellvizio is a complementary technology to manual and rob ...

2021-04-22 - MAUNA KEA TECHNOLOGIES Mauna Kea Technologies : sets up an equity financing facility with Kepler Cheuvreux

Mauna Kea Technologies sets up an equity financing facility with Kepler Cheuvreux Paris and Boston, April 22, 2021 - 5:45 PM CEST - Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-basedconfocal laser endomicroscopy (p/nCLE) platform, annou ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.3M147-4%N/A
#2
$38.8M172-2%N/A
#3
$61.8M2087%N/A
#4
$108.2M2986%N/A